Kim A. Reiss Binder, MD, describes a therapeutic approach in Phase 2 clinical trials at the Penn Center for Precision Medicine for patients with pancreatic cancer, for whom the toxicities of platinum-based chemotherapy may complicate or preclude treatment. The therapy under investigation at the PCPM will offer a combination of niraparib, a PARP inhibitor, plus immunotherapy as maintenance therapy for patients whose imaging and genetic sequencing profiles suggests a safe step-down from toxic chemotherapy. Dr. Binder is an Assistant Professor of Medicine at Penn Medicine.
EMT and Dissemination Precede Pancreatic Tumor Formation
Dr Reiss Binder’s Profile